HILS vs. ADXS, SHPH, ENVB, AIMD, CVKD, SBFM, XBIO, UPC, IBIO, and FWBI
Should you be buying Hillstream BioPharma stock or one of its competitors? The main competitors of Hillstream BioPharma include Ayala Pharmaceuticals (ADXS), Shuttle Pharmaceuticals (SHPH), Enveric Biosciences (ENVB), Ainos (AIMD), Cadrenal Therapeutics (CVKD), Sunshine Biopharma (SBFM), Xenetic Biosciences (XBIO), Universe Pharmaceuticals (UPC), iBio (IBIO), and First Wave BioPharma (FWBI). These companies are all part of the "pharmaceutical preparations" industry.
Hillstream BioPharma (NASDAQ:HILS) and Ayala Pharmaceuticals (NASDAQ:ADXS) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, dividends, valuation, analyst recommendations, media sentiment, community ranking, earnings, profitability and institutional ownership.
In the previous week, Ayala Pharmaceuticals had 1 more articles in the media than Hillstream BioPharma. MarketBeat recorded 1 mentions for Ayala Pharmaceuticals and 0 mentions for Hillstream BioPharma. Hillstream BioPharma's average media sentiment score of 0.00 equaled Ayala Pharmaceuticals'average media sentiment score.
Hillstream BioPharma's return on equity of -188.44% beat Ayala Pharmaceuticals' return on equity.
Hillstream BioPharma has a beta of 3.08, suggesting that its stock price is 208% more volatile than the S&P 500. Comparatively, Ayala Pharmaceuticals has a beta of 1.62, suggesting that its stock price is 62% more volatile than the S&P 500.
13.4% of Hillstream BioPharma shares are owned by institutional investors. Comparatively, 7.2% of Ayala Pharmaceuticals shares are owned by institutional investors. 30.2% of Hillstream BioPharma shares are owned by insiders. Comparatively, 0.6% of Ayala Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Hillstream BioPharma has higher earnings, but lower revenue than Ayala Pharmaceuticals. Hillstream BioPharma is trading at a lower price-to-earnings ratio than Ayala Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Hillstream BioPharma received 1 more outperform votes than Ayala Pharmaceuticals when rated by MarketBeat users. Likewise, 50.00% of users gave Hillstream BioPharma an outperform vote while only 0.00% of users gave Ayala Pharmaceuticals an outperform vote.
Summary
Hillstream BioPharma beats Ayala Pharmaceuticals on 9 of the 12 factors compared between the two stocks.
Get Hillstream BioPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for HILS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HILS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hillstream BioPharma Competitors List
Related Companies and Tools
